MAIA — Stock Film
STOCK FILMSCENE 1/11MAIA · $1.31
Stock Expert AI presents
MAIA
MAIA Biotechnology, Inc
~5 min film100% real numbersplain English
WHAT DOES THIS COMPANY DO?
MAIA Biotechnology, Inc. What it actually does.

Develops therapies targeting cancer. Focuses primarily on non-small cell lung cancer. Now — the numbers.

on the stock market since 2022
13 employees
$79.6M market value
Revenue last year:
$0
The loss that same year:
$22.4M
Sales don’t cover the costs; the gap drains from the cash pile every year.

The company is still in the product-building phase: its spending runs far above its sales. That only changes once the product starts selling at scale.

In the vault right now:
$8.7B
DEBT: $0
At this pace, that money lasts about 386.6 years.

At this burn rate the cash pile isn’t the pressing question — for now, time is on the company’s side.

What executives did with their own stock over the last 12 months:
57 buy0 sell

Executives buying with their own money is usually read as confidence in the company’s future.

INSIDE THE REPORT CARD

We compared this company with its own sector across five subjects.

A score of 50 means class average.

BUSINESS QUALITY
28
very weak

Clearly below the class average.

FINANCIAL STRENGTH
52
average

The cash pile is strong; debt and other items pull the grade toward the middle.

VALUATION
22
very weak

Clearly below the class average.

GROWTH
14
very weak

Clearly below the class average.

PRICE MOMENTUM
35
weak

Clearly below the class average.

WORTH WATCHING

Growth: Sales growth trails the sector average.

Valuation: The stock trades at a price that looks expensive next to its earnings; that can cap future returns.

THE COUNCIL REVIEW
9

angles, checked one by one.

The 4 that stand out are on screen; the rest came back neutral.

The council scores out of 10; report-card grades are out of 100.

STRENGTHS
A strong cash pile8/10
The shares trade freely10/10
WEAK SPOTS
The stock has lost its spark0/10
Thin profit on each sale3/10
WORTH WATCHING

Profit per Sale: The profit kept from each sale is thin.

THE FIVE-YEAR JOURNEY
A long and steep decline.

An investor who bought at the very peak is down 83% today. The business is the same; what changed most is the price — and the expectations — the market pins on it.

1
THE BRIGHT SIDE · 1/2
Strong cash, light debt

There is $8.7B in the vault; even if every debt were paid off, $8.7B would remain.

2
THE BRIGHT SIDE · 2/2
Executives are buying their own stock

Over the last 12 months, company executives reported 57 buys and 0 sells. Management buying with its own money is usually read as a good sign.

1
THE RISKS · 1/3
Small sales, big loss

A loss of $22.4M against $0 in annual sales.

2
THE RISKS · 2/3
Growth trails the sector

The growth engine is running at low revs right now. Report-card grade: 14/100.

3
THE RISKS · 3/3
The price runs ahead of the earnings

Today’s price already includes part of tomorrow’s optimism. Report-card grade: 22/100.

FINALE · THE GRADE
F
29 / 100 · MoonshotScore

On our five-subject report card, MAIA sits behind the class. A low grade doesn’t mean “doomed” — it means “big claim, small proof.”

The takeaway: MAIA is a high-risk stock — not yet profitable, and its future rides on its product catching on.

What would you like to do next?
Open the stock page →

Not covered, because the filings we hold do not carry it: the revenue breakdown.

This was a film — not investment advice.
Data: FMP & company filings
Sep 11, 2026 · stockexpertai.com · Stock Film